改性柑橘果胶的抗转移特性：一箭多雕。
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.
作者信息
Glinsky Vladislav V, Raz Avraham
机构信息
Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
出版信息
Carbohydr Res. 2009 Sep 28;344(14):1788-91. doi: 10.1016/j.carres.2008.08.038. Epub 2008 Sep 26.
Abstract
In this minireview, we examine the ability of modified citrus pectin (MCP), a complex water soluble indigestible polysaccharide obtained from the peel and pulp of citrus fruits and modified by means of high pH and temperature treatment, to affect numerous rate-limiting steps in cancer metastasis. The anti-adhesive properties of MCP as well as its potential for increasing apoptotic responses of tumor cells to chemotherapy by inhibiting galectin-3 anti-apoptotic function are discussed in the light of a potential use of this carbohydrate-based substance in the treatment of multiple human malignancies.
摘要
在本综述中，我们研究了改性柑橘果胶（MCP）的作用，它是一种从柑橘类水果的果皮和果肉中提取的复杂水溶性难消化多糖，经高pH和高温处理改性，能够影响癌症转移过程中的众多限速步骤。鉴于这种基于碳水化合物的物质在治疗多种人类恶性肿瘤方面的潜在用途，我们讨论了MCP的抗黏附特性及其通过抑制半乳糖凝集素-3的抗凋亡功能来增强肿瘤细胞对化疗的凋亡反应的潜力。
相似文献
1
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.
Carbohydr Res. 2009 Sep 28;344(14):1788-91. doi: 10.1016/j.carres.2008.08.038. Epub 2008 Sep 26.
2
Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin.
J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62. doi: 10.1093/jnci/94.24.1854.
3
Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells.
Can J Physiol Pharmacol. 2016 May;94(5):554-62. doi: 10.1139/cjpp-2015-0284. Epub 2015 Dec 16.
4
Modified citrus pectin-monograph.
Altern Med Rev. 2000 Dec;5(6):573-5.
5
Pleiotropic Effects of Modified Citrus Pectin.
Nutrients. 2019 Nov 1;11(11):2619. doi: 10.3390/nu11112619.
6
Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury.
PLoS One. 2011 Apr 8;6(4):e18683. doi: 10.1371/journal.pone.0018683.
7
Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3.
Acta Pharmacol Sin. 2018 Dec;39(12):1885-1893. doi: 10.1038/s41401-018-0004-z. Epub 2018 May 16.
8
[Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin].
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1358-61.
9
Breaking barriers: How modified citrus pectin inhibits galectin-8.
Food Funct. 2024 May 7;15(9):4887-4893. doi: 10.1039/d4fo00285g.
10
Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells.
Asian Pac J Cancer Prev. 2013;14(12):7561-8. doi: 10.7314/apjcp.2013.14.12.7561.
引用本文的文献
1
Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis.
J Mater Chem B. 2025 Mar 5;13(10):3325-3339. doi: 10.1039/d4tb01682c.
2
Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways.
Front Pharmacol. 2025 Jan 23;16:1528978. doi: 10.3389/fphar.2025.1528978. eCollection 2025.
3
Colorectal cancer and microbiota: systematic review.
Prz Gastroenterol. 2024;16(4):380-396. doi: 10.5114/pg.2024.136228. Epub 2024 Mar 11.
4
Ginseng-derived type I rhamnogalacturonan polysaccharide binds to galectin-8 and antagonizes its function.
J Ginseng Res. 2024 Mar;48(2):202-210. doi: 10.1016/j.jgr.2023.11.007. Epub 2023 Dec 6.
5
Pectin a multifaceted biopolymer in the management of cancer: A review.
Heliyon. 2023 Nov 11;9(11):e22236. doi: 10.1016/j.heliyon.2023.e22236. eCollection 2023 Nov.
6
Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment.
Onco Ther. 2022;9(2):43-55. doi: 10.1615/oncotherap.v9.i2.50.
7
Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases.
Int J Mol Sci. 2023 May 1;24(9):8116. doi: 10.3390/ijms24098116.
8
Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.
Oncol Rep. 2023 May;49(5). doi: 10.3892/or.2023.8530. Epub 2023 Mar 24.
9
Galectin functions in cancer-associated inflammation and thrombosis.
Front Cardiovasc Med. 2023 Feb 17;10:1052959. doi: 10.3389/fcvm.2023.1052959. eCollection 2023.
10
Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Nat Rev Drug Discov. 2023 Apr;22(4):295-316. doi: 10.1038/s41573-023-00636-2. Epub 2023 Feb 9.
本文引用的文献
1
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.
Am J Pathol. 2008 Feb;172(2):545-53. doi: 10.2353/ajpath.2008.070938. Epub 2008 Jan 17.
2
Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice.
Am J Pathol. 2008 Jan;172(1):247-55. doi: 10.2353/ajpath.2008.070348. Epub 2007 Dec 21.
3
Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.
Neoplasia. 2007 Aug;9(8):662-70. doi: 10.1593/neo.07433.
4
Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources.
Glycoconj J. 2007 Nov;24(8):497-507. doi: 10.1007/s10719-007-9042-3. Epub 2007 May 25.
5
Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure.
Glycobiology. 2007 Aug;17(8):805-19. doi: 10.1093/glycob/cwm054. Epub 2007 May 19.
6
Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1040-6. doi: 10.1111/j.1525-1438.2007.00916.x. Epub 2007 Apr 12.
7
Galectin-3 in apoptosis, a novel therapeutic target.
J Bioenerg Biomembr. 2007 Feb;39(1):79-84. doi: 10.1007/s10863-006-9063-9.
8
Toward a core nutraceutical program for cancer management.
Integr Cancer Ther. 2006 Jun;5(2):150-71. doi: 10.1177/1534735406288443.
9
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
Cancer Res. 2006 Mar 15;66(6):3114-9. doi: 10.1158/0008-5472.CAN-05-3750.
10
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Cancer Res. 2005 Sep 15;65(18):8350-8. doi: 10.1158/0008-5472.CAN-05-0163.
Zotero 插件